Drugs / TIPAPKINOGENE SOVACIVEC
TIPAPKINOGENE SOVACIVEC
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03260023 | Sep 2017 → Sep 2024 overdue | anal squamous cell carcinoma, cervical carcinoma, squamous cell carcinoma of penis, vulvar squamous cell carcinoma | Transgene | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01022346 | Aug 2009 → Sep 2013 | cervical intraepithelial neoplasia grade 2/3 | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIPAPKINOGENE SOVACIVEC | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108714 ↗ |
| Known as | Mva-hpv-il2 vaccine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108714 ↗ |
| Known as | RG-3484 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108714 ↗ |
| Known as | RO5217790 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01022346 ↗ |
| Known as | TG4001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03260023 ↗ |
| Known as | Tipapkinogen sovacivec | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108714 ↗ |
| Route | Subcutaneous | “RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.” NCT01022346 ↗ |